Michael Hamilton
Scientist Vividion Therapeutics
Michael Hamilton is a Scientist at Vividion Therapeutics, where his research focuses on discovering precision small-molecule therapies targeting challenging oncogenic signaling pathways. His work centers on advancing novel approaches to modulate protein–protein interactions involved in cancer biology, particularly within RAS-driven tumors. At Vividion, he contributes to the development of innovative therapeutic strategies designed to improve efficacy and tolerability beyond traditional inhibition methods. His research supports next-generation targeted cancer therapies aimed at overcoming resistance mechanisms and expanding treatment options for patients with RAS-mutant cancers.
Seminars
Tuesday 8th September 2026
Disruption of the RAS-PI3Kα Interaction Provides Enhanced Efficacy in Combination Mutant KRAS Targeting Therapies
9:30 am
- Targeting oncogenic RAS-PI3Kα signaling with small molecules that selectively block the RAS-PIK3CA interaction while preserving homeostatic PI3Kα function, improving tolerability in ways traditional active site inhibitors cannot
- Enhancing antitumor activity by combining selective RAS-PIK3CA inhibition with MAPK pathway agents, achieving dramatic efficacy improvements in preclinical RAS driven cancer models
- Countering intrinsic & adaptive resistance to direct mutant KRAS inhibitors through blockage of WT RAS-driven activation of the PI3K/AKT pathway
